AR053208A1 - Forma cristalina de un compuesto de quinolinona carboxamida - Google Patents

Forma cristalina de un compuesto de quinolinona carboxamida

Info

Publication number
AR053208A1
AR053208A1 ARP060101375A ARP060101375A AR053208A1 AR 053208 A1 AR053208 A1 AR 053208A1 AR P060101375 A ARP060101375 A AR P060101375A AR P060101375 A ARP060101375 A AR P060101375A AR 053208 A1 AR053208 A1 AR 053208A1
Authority
AR
Argentina
Prior art keywords
quinolinona
carboxamida
compound
crystal form
salt forms
Prior art date
Application number
ARP060101375A
Other languages
English (en)
Inventor
Paul R Fatheree
S Derek Turner
Adam A Goldblum
Robert Chao
Daniel Genov
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of AR053208A1 publication Critical patent/AR053208A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Una sal clorhidrato cristalina de {(1S,3R,5R)-8-[( R )-2-hidroxi-3-(metansulfonil-metil-amino)propil]-8-azabiciclo[3.2.1]oct-3-il}amida de ácido 1-isopropil-2-oxo-1,2-dihidroquinolin-3-carboxílico o un solvato del mismo. Composiciones farmacéuticas que comprenden dichas formas salinas cristalinas, métodos para utilizar dichas formas salinas cristalinas para tratar enfermedades asociadas con la actividad del receptor 5 HT4, y procesos utiles para preparar dichas formas salinas cristalinas.
ARP060101375A 2005-04-06 2006-04-06 Forma cristalina de un compuesto de quinolinona carboxamida AR053208A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66878005P 2005-04-06 2005-04-06

Publications (1)

Publication Number Publication Date
AR053208A1 true AR053208A1 (es) 2007-04-25

Family

ID=37074104

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP060101375A AR053208A1 (es) 2005-04-06 2006-04-06 Forma cristalina de un compuesto de quinolinona carboxamida
ARP170103029A AR110019A2 (es) 2005-04-06 2017-11-01 Forma cristalina de un compuesto de quinolinona-carboxamida

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP170103029A AR110019A2 (es) 2005-04-06 2017-11-01 Forma cristalina de un compuesto de quinolinona-carboxamida

Country Status (30)

Country Link
US (4) US7728004B2 (es)
EP (1) EP1874766B1 (es)
JP (2) JP5230407B2 (es)
KR (1) KR101322873B1 (es)
CN (1) CN101151264B (es)
AR (2) AR053208A1 (es)
AT (1) ATE479682T1 (es)
AU (1) AU2006232129B2 (es)
BR (1) BRPI0610657A2 (es)
CA (1) CA2603654C (es)
CY (1) CY1111275T1 (es)
DE (1) DE602006016586D1 (es)
DK (1) DK1874766T3 (es)
EA (1) EA012115B1 (es)
ES (1) ES2350495T3 (es)
HK (1) HK1110866A1 (es)
HR (1) HRP20100629T1 (es)
IL (1) IL186023A (es)
MA (1) MA29403B1 (es)
MX (1) MX2007012438A (es)
MY (1) MY151075A (es)
NO (1) NO339699B1 (es)
NZ (1) NZ561900A (es)
PE (1) PE20061310A1 (es)
PL (1) PL1874766T3 (es)
PT (1) PT1874766E (es)
SI (1) SI1874766T1 (es)
TW (1) TWI377206B (es)
WO (1) WO2006108127A2 (es)
ZA (1) ZA200708071B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7063671B2 (en) * 2002-06-21 2006-06-20 Boston Scientific Scimed, Inc. Electronically activated capture device
US7728006B2 (en) * 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
TWI351282B (en) * 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
EP1807423B1 (en) 2004-11-05 2009-05-20 Theravance, Inc. Quinolinone-carboxamide compounds
ES2332808T3 (es) * 2004-11-05 2010-02-12 Theravance, Inc. Compuestos agonistas del receptor 5-ht4.
TWI377206B (en) * 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound
EP1945632B1 (en) 2005-11-08 2013-09-18 Vertex Pharmaceuticals Incorporated Heterocyclic modulators of atp-binding cassette transporters
JP2010527357A (ja) * 2007-05-17 2010-08-12 セラヴァンス， インコーポレーテッド 腸の前処置のための運動促進剤
CH698729B1 (de) * 2007-05-30 2009-10-15 Cerbios Pharma Sa Stabile, kristalline (6S)-N(5)-Methyl-5, 6,7,8-tetrahydrofolsäure.
CA2706920C (en) * 2007-12-07 2018-02-13 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
RU2569056C2 (ru) * 2009-04-13 2015-11-20 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи Соединения-агонисты рецептора 5-нт4 для лечения расстройств познавательной способности
US20120295942A1 (en) 2010-02-01 2012-11-22 Nicholas James Devereux Pyrazolo[5,1b]oxazole Derivatives as CRF-1 Receptor Antagonists
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
ES2527849T3 (es) 2010-02-02 2015-01-30 Novartis Ag Derivados de ciclohexilamida como antagonistas del receptor de CRF
BR112012026255A2 (pt) 2010-04-07 2017-03-14 Vertex Pharma composições farmacêuticas de ácido 3-(6-(1-(2-,2-difluorbenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiridin-2-il)benzóico e administração das mesmas
PT3068392T (pt) 2013-11-12 2021-05-14 Vertex Pharma Processo de preparação de composições farmacêuticas para o tratamento de doenças mediadas por condutância transmembrana da fibrose quística (cftr)
MA49754A (fr) * 2017-07-31 2020-06-10 Alfasigma Spa Méthodes de traitement de symptômes de gastroparésie au moyen de velusetrag
WO2024061960A1 (en) 2022-09-20 2024-03-28 Alfasigma S.P.A. Velusetrag for use in the treatment of chronic intestinal pseudo-obstruction (cipo)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3122671B2 (ja) * 1990-05-23 2001-01-09 協和醗酵工業株式会社 複素環式化合物
ES2080482T3 (es) * 1990-12-28 1996-02-01 Kyowa Hakko Kogyo Kk Derivado de quinoleina.
WO1994012497A1 (en) * 1992-11-20 1994-06-09 Taisho Pharmaceutical Co., Ltd. Heterocyclic compound
JP3829879B2 (ja) * 1994-05-18 2006-10-04 大正製薬株式会社 キノリンカルボン酸誘導体
TW548103B (en) * 1997-07-11 2003-08-21 Janssen Pharmaceutica Nv Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
US7105195B2 (en) * 2003-07-25 2006-09-12 General Mills, Inc. Reduced trans fat product
ATE461192T1 (de) 2003-11-24 2010-04-15 Pfizer Chinoloncarbonsäureverbindungen mit 5-ht4- rezeptoragonistischer wirkung
TWI351282B (en) * 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US7728006B2 (en) * 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
EP1807423B1 (en) * 2004-11-05 2009-05-20 Theravance, Inc. Quinolinone-carboxamide compounds
ES2332808T3 (es) * 2004-11-05 2010-02-12 Theravance, Inc. Compuestos agonistas del receptor 5-ht4.
EP1848716A1 (en) 2005-02-17 2007-10-31 Theravance, Inc. Crystalline form of an indazole-carboxamide compound
EP1871772B1 (en) * 2005-03-02 2014-09-10 Theravance, Inc. Quinolinone compounds as 5-ht4 receptor agonists
TWI377206B (en) * 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound

Also Published As

Publication number Publication date
ZA200708071B (en) 2008-10-29
US7728004B2 (en) 2010-06-01
PT1874766E (pt) 2010-11-30
US20140256769A1 (en) 2014-09-11
CN101151264B (zh) 2011-07-06
JP5230407B2 (ja) 2013-07-10
SI1874766T1 (sl) 2010-12-31
AR110019A2 (es) 2019-02-13
CA2603654A1 (en) 2006-10-12
NO339699B1 (no) 2017-01-23
NO20075574L (no) 2007-11-02
AU2006232129B2 (en) 2012-07-12
HK1110866A1 (en) 2008-07-25
JP2008535848A (ja) 2008-09-04
PL1874766T3 (pl) 2011-02-28
MX2007012438A (es) 2007-12-05
PE20061310A1 (es) 2007-01-23
US20160095849A1 (en) 2016-04-07
CY1111275T1 (el) 2015-08-05
DK1874766T3 (da) 2010-12-06
EP1874766B1 (en) 2010-09-01
HRP20100629T1 (hr) 2010-12-31
JP2012153725A (ja) 2012-08-16
WO2006108127A3 (en) 2007-01-04
US20100197728A1 (en) 2010-08-05
MY151075A (en) 2014-03-31
IL186023A (en) 2011-09-27
BRPI0610657A2 (pt) 2010-07-13
IL186023A0 (en) 2008-01-20
MA29403B1 (fr) 2008-04-01
ES2350495T3 (es) 2011-01-24
AU2006232129A1 (en) 2006-10-12
TW200643020A (en) 2006-12-16
NZ561900A (en) 2010-12-24
US20060229332A1 (en) 2006-10-12
CA2603654C (en) 2014-05-27
EP1874766A2 (en) 2008-01-09
KR101322873B1 (ko) 2013-10-30
KR20070116988A (ko) 2007-12-11
EA200702161A1 (ru) 2008-04-28
US8658671B2 (en) 2014-02-25
US9402840B2 (en) 2016-08-02
ATE479682T1 (de) 2010-09-15
CN101151264A (zh) 2008-03-26
TWI377206B (en) 2012-11-21
WO2006108127A2 (en) 2006-10-12
US9126994B2 (en) 2015-09-08
EA012115B1 (ru) 2009-08-28
DE602006016586D1 (de) 2010-10-14

Similar Documents

Publication Publication Date Title
AR053208A1 (es) Forma cristalina de un compuesto de quinolinona carboxamida
ECSP10010008A (es) (2s,3r)-n-(2-((3-piridinil)metil)-azabiciclo[2.2.2]oct-3- il)benzofuran-2-carboxamida, formas de sal novedosas, y métodos de uso de los mismos
AR066130A1 (es) Formas cristalinas de saxagliptina y procesos para preparar las mismas
BRPI0917608B8 (pt) formulação de droga oral para a redução de potencial efeito abusivo, processo para a fabricação de uma formulação de droga e seu uso
AR109224A2 (es) Formas de sales cristalinas de un compuesto 8-azabiciclo[3,2,1]octano, composición farmacéutica que las comprende, procesos para prepararlas, compuesto intermediario de síntesis relacionado y su uso para la fabricación de un medicamento
HN2001000268A (es) Formas de sal de amida de acido 3 - (4-bromo - 2, 6 - difluorobenciloxi) - 5 - [3 - (4 - pirrolidin - 1 - ilbutil) ureido] isotiazol - 4 - carboxilico y metodo de produccion.
CO6660435A2 (es) Una forma cristalina de clorhidrato de (r) -7- cloro-n- (quinuclidin -3-il)benzo[b] tiofeno-2- carboxamida monohodratado
CL2012002540A1 (es) Hidrato de hidrocloruro de agomelatina; forma cristalina; metodo de preparacion; composicion farmaceutica ; y su uso para el tratamiento de trastornos del sueño, estrés, ansiedad, depresion mayor, enfermedades cardiovasculares, entre otras.
CO6460737A2 (es) N-((1r,2s,5r)-5-(tert -butilamino)-2-((s)-3-(7-tert-butilpirazolo[1.5-a][1.3.5]traizin -4-ilamino)-2-oxopirrolidin-1-il)ciclohexil)acetamida, un modulador dual de la actividad del receptor de quimiocinas, formas cristalinas y procesos
AR084832A1 (es) Derivado cristalino de oxazina
ECSP099602A (es) Sales de adición de ácido, hidratos y polimorfos de la etil-amida del ácido 5-(2,4-dihidroxi-5-isopropil-fenil)-4-(4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxílico, y formulaciones que comprenden estas formas
BR112013033831A2 (pt) composição farmacêutica oftalmológica tópica que contém regorafenib
CO7071134A2 (es) Formas cristalinas de cloruro de hidrógeno de 1-(3-terc-butil-1-p-tolil-1h-pirazol-5-il)-3-(5-fluoro-2-(1-(2-hidroxietil)-1h-indazol-5-iloxi)bencil)urea
EA201270573A1 (ru) Гранулированный в расплаве цинакальцет
CL2011001829A1 (es) 3&#39;-n-desmetil-4&#39;&#39;-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.
GT200600421A (es) Formas cristalinas polimórficas de la sal de di-sodio del ácido n-(5-clorosaliciloil)-8-aminocaprilico
CO6390054A2 (es) Formas cristalinas de un compuesto 3-carboxipropil-aminotetralina
AR063924A1 (es) Analogos de pirazol
BR112015007991A2 (pt) derivados de etinila como moduladores da atividade do receptor de mglur5
AR051933A1 (es) Proceso para la preparacion de n-(3,5 dicloropirid-4-ilo)-4-difluormetoxi-8-metano sulfonamido-dibenzo[b,d] furano-1-carboxamida
BR112014014202A2 (pt) formas sólidas de cloridrato de (1r,4r)-6&#39;-fluoro-n,n-dimetil-4-fenil-4&#39;,9&#39;-dihidro-3&#39;h-espiro-[ciclohexano-1,1&#39;-pirano[3,4,b]indol]-4-amina
BR112013029927A2 (pt) &#34;compostos antibióticos, composições farmacêuticas, usos das referidas composições e métodos de produção dos referidos compostos&#34;.
BRPI0913736A2 (pt) Composto, processo para a preparação do composto, composição farmacêutica e método para o tratamento de uma desordem do sistema nervoso central
AR065530A1 (es) Sal hidrocloruro de ( 1r; 2r;3s;5s)-2-metoximetil-3-(3;4-diclorofenil)-8-azabiciclo(3.2.1)octano, metodo para fabricar una forma farmaceutica de la misma, dosis liquida que la comprende y forma farmaceutica que comprende un sustrato de vehiculo y dicha sal
CU20090151A7 (es) Sales de adición de ácido, hidratos y polimorfos de la etil-amida del ácido 5-(2,4-dihidroxi-5-isopropil-fenil)-4-(4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxílico, y formulaciones que comprenden estas formas

Legal Events

Date Code Title Description
FC Refusal